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Parkinson’s disease (PD) is the second most common neurodegenerative 
disorders worldwide1 and is a chronic and progressive condition,2,3 which 
affects 1 % of the older population (>60 years of age).4 Over the years, 
major research has been focused on the motor impairments in PD, 
which has contributed to the development of symptomatic treatments 
for these patients. Evidence also demonstrates that PD patients have 
sensory impairments and chronic pain, which reduce their quality of life 
dramatically. Approximately 43 % of PD patients suffer from pain in general. 
There is no cure yet available and the number of affected PD patients is 
increasing, which highlights an existing socioeconomic burden.1
PD is characterized as a primary neurodegenerative disorder5 due to 
a dysfunction that might occur in the basal ganglia network following 
degeneration of dopaminergic pigmented neurons in the substantia nigra 
pars compacta, which gives rise to a significantly reduced dopaminergic 
deficit in striatum, especially in the putamen part.4 Several studies suggest 
that an abnormal basal ganglia function in PD can modulate pain directly 
by increasing or reducing the spread of nociceptive signals or indirectly by 
changes in affective and cognitive processes related to pain perception.6,7 
Over the past decade, it has been gradually revealed that sensory perception 
in PD patients has been altered8–10 and the putative dysfunction in the basal 
ganglia is thought to lead to pain and sensory impairment in these patients. 
The impairment of the sensory system is a less-explored area in PD. There 
are only few studies available applying sensory tests in PD patients with 
conflicting results.11,12 One study showed that PD patients had a lower 
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threshold in both the cold pressure test (CPT) and pressure pain threshold 
(PPT) test13 and another study showed increased hypersensitivity to cold 
pain threshold (CPT) in PD patients compared with healthy subjects.6 
However, there is a still uncertainty about this alteration in sensory 
perception as some studies have not been able to demonstrate any 
significant change.10 It remains to be determined whether PD patients 
suffer from sensory disturbances in terms of hyposensitivity or 
hypersensitivity in response to application of a painful or nonpainful 
stimulus and to what extent. In addition, it is still not clear whether 
sensory impairment is different in PD patients who suffer from a long-
term spontaneous chronic pain, who also often have a poor quality of 
life, in comparison with those who do not have pain on a daily basis for 
a long term. It is also not known whether different PD medications have 
a possible effect on the perception of pain and peripheral sensory input. 
The primary aim of this study was to investigate whether PD patients 
have an altered sensory perception that might lead to an increased pain 
perception in response to noxious and non-noxious stimuli. We also 
investigated whether different medications taken by the PD patients 
can have an effect on responsiveness to the applied sensory tests. We 
proposed that some alterations in pain and sensory perception will be 
detected in mechanical and thermal perception in PD patients compared 
with healthy subjects and that drugs that might affect the sensory 
alterations are most likely levodopa preparation and dopamine agonists.
Materials and Methods 
Subjects and Study Design
Twelve PD patients (nine males, three females with the mean age ± 
standard deviation [SD], 68.67±5.5 years) were recruited through 
arrangements with the chief physician, Ali Karshenas, Department 
of Neurology, Aalborg University Hospital, Denmark. Patients were of 
Caucasian descent, either with PD-related pain or without pain. 
Patients >60 years who had been diagnosed ≤5 years with no central 
or peripheral disorders were included. Patients with pain (except the 
pain related to PD—defined as pain experienced in PD patients due to 
no other reason than PD based on the European Parkinson’s Disease 
Association), on painkillers, psychical disorders such as schizophrenia 
and dementia, mental retardation, memory impairment, or a Mini Mental 
State Examination (MMSE) score <24 (see description below) and other 
disorders of the central nervous system (CNS) or polyneuropathy were 
excluded from the study. The patients did not take alcohol, caffeinated 
drinks, or smoke 24 hours before the experiments. In addition, 12 best-
matched healthy volunteers (eight males, four females with the mean 
age ±  SD, 67.5±5.39 years) of Caucasian descent were included as 
controls. The healthy volunteers were recruited through public notices 
posted at Aalborg University Hospital, Denmark, and social media. Having 
pain or taking any painkillers were among the exclusion criteria for 
healthy volunteers. The experiments took place in the outpatient clinic, 
Department of Neurology, Aalborg University Hospital, Denmark, and the 
participants attended one session, which lasted for about 1 hour.
PD patients (with pain and without pain) and healthy subjects were all 
screened and written informed consent was obtained from all participants 
before the start of the experiments. The state of patients’ mood (e.g. 
depression) was not determined through standard questionnaires or test; 
however, the medications taken by patients were recorded to summarize 
all medications taken by the patients (e.g. antidepressants). PD medications 
included: Sifrol®, Sinemet®, Madopar® Quick®, Mylan-Selegiline®, Stalevo®, 
Exelon®, Requip depot®, Madopar®, Eldepryl®, Requip®, and Azilect®. 
Other medications were mainly associated with cardiovascular matters 
and included: Ramipril, Norvasc®, Nifedipine, Corodil®, Cordarone®, 
Metoprolol, Asasantin®, Simvastatin, Hjertemagnyl®, Marevan®, Centyl®, 
Diural®, Ancozan®, and Furix®. Some patients were also on the following 
medications: Tolterodin, Metformin, Kaleorid®, Folimet®, Methotrexate, 
Euthyrox®, Eltroxin®, Zolpidem, and Gabapentin. 
The Ethical Committee of the Region Nordjylland Denmark approved the 
study protocol (N-20130073) and the experiments were performed in 
accordance with the Declaration of Helsinki.
Measurements
Evaluation of Cognitive Function 
MMSE and clock face test were used as screening instruments to assess 
the cognitive function and investigate cognitive disturbances to ensure 
that the participants understood the visual analog scale (VAS) (see 
description below) and the quantitative sensory tests. The MMSE test is 
a brief standardized method to assess the mental status (score 0–30). 
Participants with a score <24 were excluded. The clock face test was 
approved without errors or minimal abnormality in the location of the 
hands and numbers.
Evaluation of Pain Perception and Daily  
Life Activities 
The McGill pain questionnaire was used for PD patients with pain. This 
questionnaire was used to get an overview over the location of chronic 
pain in the PD patients with pain. In the experimental session, the stimuli 
were given on both forearms (centrally between elbow and wrist) in a 
supine position, on the dominant hand (few centimetres over the wrist), 
and on the lumbar part of the back (around vertebrae lumbales LIII on 
the left side) (see Figure 1). To assess the sensitivity and pain threshold 
to nonpainful and painful stimuli, a VAS scale was applied after all the 
mechanical tests and during/after the thermal test. The VAS scale was 
used in the way that the participants indicated a number from 0 to 10; in 
which 0 was “no pain” and 10 was the “worst possible pain.” The World 
Health Organization (WHO) performance status was used to provide an 
overview of PD patients’ general well-being and activities of daily life.
Dynamic Mechanical Allodynia in Response  
to Manual Light Brush
Subjects were seated with both forearms rested on the table in a supine 
position. A standardized brush (SENSELab Brush-05, Somedic, Hörby, 
Sweden) was used. They were asked to keep their eyes closed during 
the test. The handheld brush was moved across the skin for five times 
with a speed of 1–2 cm/second and with an angle of approximately 45˚. 
The brush was applied alternately from right to left and each stroke was 
performed from distal to proximal direction (see Figure 1). Each stroke 
was 5 cm in length over the skin and the test was performed three times 
for each forearm (interstimulus interval 3–5 second), after which the 
subjects were asked to rate the pain intensity on a VAS scale (a total three 
times for each forearm). This test was also performed in the lumbar part 
(see Figure 1), on the left side, applying the same procedure, while the 
subjects rested on their stomach on a couch. 
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Mechanical Pain Sensitivity in Response to  
Pinprick Stimulation 
Seven weight-calibrated pinprick stimulators were applied one by one with 
one prick at a time in a random order. The handheld pinprick stimulator 
(Pinprick Stimulator Set, MRC System GmbH, Heidelberg, Germany) 
consists of seven weighted flat-tipped needles (8mN, 16mN, 32mN, 64mN, 
128mN, 256mN, and 512mN) with a contact area of 0.2mm2. This test was 
carried out in a dotted line in both forearms rested at supine position 
on the table, while the subjects were seated. The subjects were asked 
to keep their eyes closed during the stimulations. Each stimulation was 
repeated three times (interstimulus interval 2–4 seconds) with an angle of 
approximately 90˚ for each forearm. Stimulators were applied alternately 
from right to left forearms (see Figure 1) and only one forearm at a time 
was stimulated with seven weighted needles. During the pinprick test, the 
subjects were asked to rate their pain intensity to each stimulus on a VAS 
scale. The pinprick stimulators were also applied on the back (see Figure 1), 
with the same procedure as the forearm. 
Pressure Pain Threshold 
A handheld pressure algometer (Somedic, Hörby, Sweden) was applied, 
which consisted of a gun-shape holder connected to a probe with a 
circular sensor tip covered with a rubber material with an area on 1 cm2. 
The pressure rate was set for applied force of 30 kPa/s. The digital display 
on the pressure algometer showed the pressure (kPa). The subjects 
pressed a stop key, the first time they felt that the pressure turned to pain. 
This froze the number corresponding to the pressure on the display, which 
was noted as the PPT (KPa). The PPT was assessed on both forearms and 
the lumbar part (see Figure 1). For this test, the subjects were seated with 
their forearms resting on the desk in a supine position and instructed to 
use a handheld button to stop the delivered pressure when it reached the 
point that they felt it uncomfortable. At this point, they were also asked to 
rate their level of unpleasantness on a VAS scale. This test was performed 
three times with an angle of approximately 90˚ on each forearm with a 
resting period of 60 seconds in between each stimulus. The pressure 
algometer was used with the same procedure on the lumbar part. 
Cold Pressor Test 
First, the dominant hand was immersed in a bucket of water (30˚C) for 2 
minutes in order to provide fairly similar hand temperature. Subsequently, 
the CPT was carried out and the hand was immersed in a bucket of ice 
water (5˚C) for maximum of 2 minutes. The hand was immersed in ice 
water a few centimetres above the wrist (see Figure 1). The subjects were 
instructed to withdraw their hand when it was uncomfortable or painful. 
Pain intensity was rated on a VAS scale during and after the experiment. 
Three measurements were made at 30s, 60s, and at the termination of the 
test (tolerance time). The subjects were informed that there was a limited 
maximum possible tolerance time at 2 minutes. Therefore, if subjects 
removed their hand before this cut-off, the tolerance time was noted; 
otherwise, 2 minutes was noted for the tolerance time of a subject who 
kept the hand until to the end. The final pain intensity was also measured 
on a VAS scale right after the hand removal. 
The CPT was then followed by a PPT test. The dominate hand was tested 
by the pressure algometer before and after the CPT and PPT were noted. 
The subjects were also asked to rate their unpleasantness on a VAS scale.
Statistical Analysis 
All data were first analyzed for normality using the Shapiro-Wilk test. 
Whenever the data were distributed normally, parametric tests were applied 
for statistical comparison. Otherwise, nonparametric tests were applied. 
The brush, the pinprick
stimulators, and the
pressure algometer
were used in these
locations.
The location of 
where the cold water 
affected the dominant 
hand (right or left)
Figure 1: Stimulated Areas in Healthy Subjects and Parkinson’s Disease Patients
The cross in the figure shows the area where the subjects were stimulated with a brush, pinprick stimulators, and the pressure algometer. The line shows where healthy subjects and Parkinson’s 
disease patients were stimulated with cold water. The body charts are adapted from the McGill Pain Questionnaire.
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An unpaired nonparametric test (Mann-Whitney U test) was used to compare 
pain intensity (e.g. pain tolerance and pain threshold) in sensory tests. In order 
to evaluate the most sensitive area in PD patients an unpaired nonparametric 
test (Kruskal Wallis U test) was used. Furthermore, a paired nonparametric 
test (Friedman) was applied to test whether there was an exponential curve 
in the assessment of pain intensity among the participants. Finally, a multiple 
linear regression analysis was applied to test any correlation in the pinprick 
test for each stimulator in each area in both groups.
The results are presented as the median and interquartile range (IQR, 
25–75th) and the significance level was defined as p<0.05. All data were 
organized in Excel 2013 and all statistical calculations were performed in 
SPSS version 18.0 (IBM, Hong Kong) and graphs were created in SigmaPlot 
12.0. (Software Inc., Germany).
Result
Subjects 
All participants completed the study with no safety concerns or complaints. 
There was no significant sex (p=0.660) and age (p=0.311) difference 
between PD patients and healthy controls. There was no statistically 
significant difference between groups in MMSE score (p=0.060) either. 
Five PD patients (41.7 %) had chronic pain and completed the McGill 
Pain Questionnaire (see Figure 2). All patients had chronic pain in the 
upper part of the body and 60 % had chronic pain in the lower part. 
The performance status showed that healthy subjects had normal 
function (WHO; 0) and the PD patients had a WHO status between 0 and 2, 
which means that 58.33 % had decreased function in the daily activities. 
All patients were on the PD medications (dopamine agonists and/or 
levodopa preparation) and 33.33 % received only one drug and 66.66 % 
had >1. The two most frequently taken medications were Sifrol® (33.33 %) 
and Sinemet® (66.66 %). 
Dynamic Mechanical Allodynia 
The results from brush test showed that 58.33 % of the PD patients suffered 
from dynamic mechanical allodynia (DMA) (allodynic area: right-, left 
forearm, and lower back). The median of both groups were calculated for 
all three locations (right-, left forearm, and lower back) and Mann-Whitney 
test showed that the PD patients were more sensitive to brush test than the 
healthy subjects (Pright forearm =0.021, Pleft forearm =0.025, and Plower back=0.002). The 
test revealed that PD patients were most sensitive in lower back. 
Static Mechanical Hyperalgesia
An average for all seven pinprick stimuli was calculated from three areas 
(right-, left forearm, and lower back) in each subject and the Mann-Whitney 
test revealed that there was a statistically significant difference between 
healthy subjects and PD patients by stimulation of the lower back (p<0.001). 
There was no difference between the groups by pinprick stimulation of the 
right (p=0.769) and left forearm (p=0.838). The average of each stimulus 
was calculated for all participants. Mann-Whitney test revealed that PD 
patients had rated their pain intensity higher than healthy subjects. The 
perception of pain was significantly increased in PD patients (p for all seven 
stimulators: <0.001). The three curves showed a clear difference between 
healthy subjects and PD patients (see Figure  3) following stimulation of 
A
D E
B C
Figure 2: The Pain Location in Parkinson’s Disease Patients
The figure presents how the five Parkinson’s disease (PD) patients with pain outlined their pain using the McGill Pain Questionnaire. Patient A (no. 13), B (no. 14), C (no. 15), and D (no. 16) had pain 
in more than one place and patient E (no. 17) only had pain at one place, but over a wider area. The patients describe the symptoms as muscle contraction, stiffness/tight, tiring/exhausting, and 
pinching, aching, and muscle tenderness. The body charts are adapted from the McGill Pain Questionnaire. 
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right forearm, left forearm, and lower back. Kruskal Wallis test revealed no 
difference between the two groups in relation to the area that were the most 
sensitive. The test was also used to calculate the median for all seven stimuli 
in both groups, which revealed a difference between these two groups, 
confirming the existence of hyperalgesia in the PD patients (hyperalgesic 
areas: right-, left forearm, and lower back). Friedman test made it also clear 
that the higher the stimulus, the higher was the pain intensity (p<0.001). 
A multiple linear regression analysis did not show a significant result. 
Conditioned Pain Modulation 
Pressure Pain Threshold 
A Mann-Whitney test showed that there was a statistically significant 
difference in PPT values between PD patients and healthy subjects 
before (p=0.011) and after (p=0.050) the CPT test (see Figure 4). There 
was no significant difference in the nondominant hand (p=0.065) or 
lower back (p=0.106).
Tolerance Time—Cold Pressor Test 
All healthy subjects and nine PD patients completed 30 seconds or more in 
the cold water test. The test showed a difference in pain intensity between 
these two groups, but the difference was not significant (p=0.183). Only 
nine healthy subjects and five PD patients  completed the test by 60 
seconds or more. There was no statistically significant difference between 
the rated pain intensity in healthy subjects and PD patients (p=0.402). The 
median of pain on the VAS scale was 6.00 (5.25 to 8.00) and the results 
showed that the pain intensity was rated higher in PD patients compared 
with healthy subjects, but not significantly higher (p=0.078). The Mann-
Whitney test revealed a significant difference in tolerance time between 
healthy subjects and PD patients (p=0.016) (see Figure 5). Healthy subjects 
had a higher tolerance time compared with the PD patients (85.42 versus 
52.17 seconds) (see Figure 5). When performing the cold water test it was 
observed that the PD patients started to shake significantly more than they 
did before the test. The 30˚ water did not affect the PD patients.
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Figure 3: Hyperalgesia in Response to Pinprick Stimuli in the Test Areas Investigated in Parkinson’s Disease 
Patients and Healthy Subjects
*Indicates significant difference (p<0.05) between the healthy subjects and Parkinson’s disease (PD) patients. The error bars indicate standard deviation (SD). Difference between healthy 
subject and PD patients are demonstrated in the right forearm (Graph A), in the left forearm (Graph B), and in the lower back (Graph C). Each point is the average of each stimulator in all graphs. 
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Discussion 
The current study investigated the sensory characteristics in PD patients 
compared with the healthy subjects. There are only few studies available on 
sensory tests in PD patients with conflicting results.11,12 Our results revealed 
that PD patients suffered from allodynia to brush and hyperalgesia to prick 
stimulation in the back and in both forearms. PPT test revealed that the PD 
patients had lower threshold in the dominant hand both before and after 
the CPT, but were not different in the nondominant hand and the back. 
PD patients also had shorter tolerance time in the CPT test. There was no 
association between sensory impairment and PD medication. It should be 
highlighted that the present study’s population is limited; a larger population 
is required to reveal whether the obtained results and conclusions would 
follow similarities in deviated sensory responses in PD patients. 
Spontaneous Pain in Parkinson’s Disease 
In the current study, five of the PD patients had PD related pain (41.7 % 
of the patients had chronic pain), which is in accordance with the results 
of Chaudhuri et al.,14 who found that approximately 40.0–45.9  % of PD 
patients suffer from Parkinson-related pain. Furthermore, the PD patients 
describe their symptoms and marked their pain area on the McGill Pain 
questionnaire, which is in accordance with the symptoms found by Ford 
et al.5 and Fil et al.15 One study16 has investigated the association between 
pain and motor complications in PD patients with and without pain and 
shown a significant association of pain with motor problems. This finding 
suggests that in PD pain may occur secondary to motor complications.
Allodynia and Hyperalgesia 
We demonstrated here that PD patients had an altered perception in 
response to the light touch and had increased pain intensity in response 
to an already painful stimulus compared with healthy subjects. Our results 
showed that PD patients without pain had the highest pain intensity to light 
touch in comparison with PD patients with pain. This might indicate that 
the patients without pain were more sensitive to a nonpainful stimulus 
than the PD patients with pain, but both were allodynic in comparison with 
healthy subjects. Based on our knowledge, allodynia has not been tested 
in PD patients before. Our results showed that 58.33 % of PD patients had 
discomfort to the nonpainful stimuli by brush. PD patients with pain rated 
the pain intensity higher than PD patients without pain to a painful stimulus. 
The stimulus-dependent-response in PD patients showed increased pain 
intensity to painful stimuli and that the PD patients felt higher pain by larger 
stimulation compared with healthy subjects. The study also investigated 
the most sensitive area to pinprick test, the lower back was found to be the 
most sensitive region, followed by the right forearm, and the lowest pain 
intensity was in left forearm. However, the result did not show a significant 
difference between the test areas in the right and left forearms. We could 
not find similar studies and there would be no point for comparison.
It is not well known that what causes the perception of allodynia and 
hyperalgesia in PD patients. However, animal studies have shed light on 
some possible mechanisms that might be involved in development of 
allodynia in PD. Wisam Dieb et al.17 investigated DMA in a rat model of PD. 
The rats received an injection of 6-hydroxy dopamine bilaterally to produce 
a lesion in the nigrostriatal dopaminergic pathways. This study showed 
significant DMA in the orofacial area, in response to tactile stimulus and 
the rats received a dopamine 2-receptor agonist (Bromocriptine), a PD 
medication; the DMA was dramatically reversed compared with control 
rats that were treated with saline. This study demonstrated that a lesion 
in the nigrostriatal pathways could result in DMA. Possibly the neuronal 
loss of dopaminergic neurons results in an abnormal perception of the 
tactile and nociceptive information or result in central sensitization and 
presence of allodynia in PD. 
Previous studies have shown that CNS disorders can cause altered 
perception to touch.18 Brush stimulation activates primary sensory 
neurons encoding signals for low intensity (Aβ-fibers), which under 
normal conditions should be perceived as sensation of touch.19 
Stimulation with pinprick activates Aδ- and C-fibers (encoding for high 
Figure 4: Pressure Pain Threshold before and after 
Cold Water Stimulation in Parkinson’s Disease 
Patients and Healthy Subjects
*Indicates significant difference (p<0.05) between the healthy subjects and Parkinson’s disease 
(PD) patients. The error bars indicate standard deviation (SD). The figure illustrates a statistically 
significant difference in pain threshold between healthy subjects and PD patients before and 
after cold water stimulation. 
Figure 5: Tolerance Time in Cold Pressor Test in 
Parkinson’s Disease Patients and Healthy Subjects
*Indicates significant difference (p<0.05) between the healthy subjects and Parkinson’s disease 
(PD) patients. The error bars indicate standard deviation. 
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intensity) and normally should be perceived as pain. However, under 
pathologic conditions, central sensitization might occur, which is defined 
as increased response to e.g. light touch.19,20 Our observation suggests 
that the PD patients might have a state of central sensitization, which 
leads to increased synaptic ascending transmission and a decrease in 
the descending inhibition.19,21 Normally, the Aβ-fibers become activated 
by touch to a light stimulus, such as brushing, but when allodynia occurs 
it is proposed that the signals from myelinated Aβ-fibers intersect to 
unmyelinated C-fibers, which causes pain in response to a nonpainful 
stimulus.19 It is speculated that the PD patients were affected on both 
pathways and that the interaction between afferent and efferent neurons 
in the spinal cord has an impact on central sensitization, which possibly 
reflects on responsiveness of PD patients to painful stimulus.22 
This study supports the notion that the PD patients have altered pain 
perception and this novel observation might contribute to future 
investigations and extend the literature of allodynic and hyperalgesic 
conditions in PD patients. In the longer term, increased knowledge on 
impaired sensory function in PD may lead to a better diagnostic stratification 
of PD patients, and development of newer medications to help PD patients 
overcoming sensory disturbances along with motor dysfunction. 
Conditioned Pain Modulation—Function of 
Descending Inhibitory Pain Pathways 
PD patients rated higher pain intensity than healthy subjects in response to 
cold stimulation by immersion of hand in ice water, however, the difference 
between these two groups were not significant. The drop out and even 
numbers per group for comparison might have caused insufficient 
power for statistical analysis. There was however a significant difference 
in tolerance time between healthy subjects and PD patients, where PD 
patients had shorter tolerance time than healthy subjects. The result 
revealed a difference between PD patients with pain that withdrew their 
hand several minutes before PD patients without pain. The PD patients 
were more sensitive than healthy subjects, however, a difference between 
the PD patients with pain and without pain was not observed. The PPT is 
believed to test the deep pain sensitivity transmitted by Aδ- and C-fibers.23 
Our results indicate that these nociceptive fibers were activated in PD 
patients and in healthy subjects, but the perception of pain occurred faster 
in PD patients. The PD patients complained of discomfort the first few 
seconds, after which the pain was initiated. This indicated that the activation 
of Aδ-fibers were initiated in the beginning of the test and furthermore an 
activation of C-fibers occurred, when the PD patients felt an uncomfortable 
pain by performing the CPT.23 The CPT test, however, showed a significant 
difference between PD patients and healthy subjects, where the PD 
patients had higher PPT values before the cold test compared with PPTs 
after the test. After the CPT, PD patients were more sensitive, which might 
be due to central sensitization present in these patients. There is no similar 
study that has investigated the PPT before and after the CPT in PD patients. 
Vela et al.13 investigated the PPT in PD patients with and without 
administration of PD medications in comparison with healthy subjects 
groups and found a significant difference in all four investigated areas 
(frontal bone, C5-C6 joint, the second metacarpal, and the tibialis anterior 
muscle). We did not find a significant difference in PPT values between 
the right and left forearm in PD patients and healthy subjects, but found a 
tendency that the PD patients had lower pressure in the lower back and 
the nondominant hand. Due to the lack of data available for other studies 
on CPT in PD patients, comparison of results obtained here with other 
similar studies is not possible. 
This area needs future investigation to clarify the underlying mechanism, 
such as the functionality of the descending inhibitory pain pathways and 
the tolerance to cold water stimulation. Our findings support that the PD 
patients have altered perception in deep pain sensitivity. 
In summary, this pilot study confirmed the existence of sensory and pain 
disturbances in PD patients in comparison with healthy subjects that 
might be due to the loss of dopaminergic neurons, which might have an 
impact on the nigrostriatal pathways leading to an abnormal basal ganglia 
function and disturbances in afferent and efferent pathways of pain 
perception. Changes in pain perception might also be due to peripheral 
pain receptors, structures such as the periaqueductal gray matter, and 
nondopaminergic neurotransmitter systems. Larger studies are needed 
to confirm the results obtained in the present study. n
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